Literature DB >> 9816044

p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.

I Shibagaki1, H Tanaka, Y Shimada, T Wagata, M Ikenaga, M Imamura, K Ishizaki.   

Abstract

We examined the relationship between p53 mutation, murine double minute 2 (MDM2) gene amplification, and human papillomavirus (HPV) infection in 72 esophageal squamous cell carcinomas. We identified p53 mutations in 29 tumors (40.3%) by PCR-single-strand conformation polymorphism analysis and direct sequencing. Amplification of the MDM2 gene was detected by Southern blot hybridization in 13 (18.1%) of 72 tumor tissues and in 4 (33.3%) of 12 cultured esophageal squamous cell lines. All four cell lines with MDM2 amplifications showed overexpression of the MDM2 mRNA in Northern blotting. We observed HPV infection in 15 (20.8%) of 72 tumor tissues by specific PCR amplification and Southern blot hybridization. In most tumors, amplification of the MDM2 gene or infection of HPV was not associated with p53 mutations, except in four cases with p53 mutation and MDM2 amplification, and three cases with p53 mutation and HPV infection. Since p53 mutations, MDM2 overexpression, and HPV infection are all considered to abrogate the normal function of p53 protein, each of these genetic changes may be equally important in tumorigenesis. In addition, we found that patients with MDM2 amplification exhibited a significantly shorter survival period (P = 0.0053).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9816044

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

Review 1.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

Review 2.  Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers.

Authors:  Ioannis N Mammas; George Sourvinos; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2010-07-18       Impact factor: 3.201

3.  Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy.

Authors:  Y Shimada; M Imamura; I Shibagaki; H Tanaka; T Miyahara; M Kato; K Ishizaki
Journal:  Ann Surg       Date:  1997-08       Impact factor: 12.969

4.  Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.

Authors:  Kailiang Zhao; Yang Yang; Guang Zhang; Chenfeng Wang; Decai Wang; Mian Wu; Yide Mei
Journal:  EMBO Rep       Date:  2018-01-02       Impact factor: 8.807

5.  Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE.

Authors:  Casimiro Gerarduzzi; Anna de Polo; Xue-Song Liu; Manale El Kharbili; John B Little; Zhi-Min Yuan
Journal:  J Biol Chem       Date:  2016-10-24       Impact factor: 5.157

6.  NMR structure of a complex between MDM2 and a small molecule inhibitor.

Authors:  David C Fry; S Donald Emerson; Stefan Palme; Binh T Vu; Chao-Min Liu; Frank Podlaski
Journal:  J Biomol NMR       Date:  2004-10       Impact factor: 2.835

Review 7.  HPV infections and oesophageal cancer.

Authors:  K J Syrjänen
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

8.  Correlation of p53, MDM2 and p14(ARF) protein expression in human esophageal squamous cell carcinoma.

Authors:  Tzu-Hao Cheng; Po-Kuei Hsu; Anna Fen-Yau Li; I-Chun Hung; Min-Hsiung Huang; Han-Shui Hsu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-02       Impact factor: 4.553

Review 9.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

Review 10.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.